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Abstract: Background: agonistic autoantibodies (agAABs) against G protein-coupled receptors
(GPCR) have been linked to cardiovascular disease. In dementia patients, GPCR-agAABs against
the α1- and ß2-adrenoceptors (α1AR- and ß2AR) were found at a prevalence of 50%. Elimination of
agAABs by immunoadsorption (IA) was successfully applied in cardiovascular disease. The IMAD
trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia and agonistic
autoantibodies against alpha1A-adrenoceptor) investigates whether the removal of α1AR-AABs
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by a 5-day IA procedure has a positive effect (improvement or non-deterioration) on changes of
hemodynamic, cognitive, vascular and metabolic parameters in patients with suspected Alzheimer’s
clinical syndrome within a one-year follow-up period. Methods: the IMAD trial is designed
as an exploratory monocentric interventional trial corresponding to a proof-of-concept phase-IIa
study. If cognition capacity of eligible patients scores 19–26 in the Mini Mental State Examination
(MMSE), patients are tested for the presence of agAABs by an enzyme-linked immunosorbent
assay (ELISA)-based method, followed by a bioassay-based confirmation test, further screening
and treatment with IA and intravenous immunoglobulin G (IgG) replacement. We aim to include
15 patients with IA/IgG and to complete follow-up data from at least 12 patients. The primary
outcome parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr
of brain tissue determined by magnetic resonance imaging with arterial spin labeling after 12 months.
Conclusion: IMAD is an important pilot study that will analyze whether the removal ofα1AR-agAABs
by immunoadsorption in α1AR-agAAB-positive patients with suspected Alzheimer’s clinical
syndrome may slow the progression of dementia and/or may improve vascular functional parameters.
Keywords: Alzheimer’s clinical syndrome; dementia; immunoadsorption; autoantibodies;
α1-Adrenergic receptor
1. Introduction
Nearly 50 million people worldwide suffer from Alzheimer’s disease (AD) or other forms of
dementia, and around 10 million new cases emerge every year, leading to a number of 150 million
affected people expected in 2050 [1–3] Dementia has a lifetime prevalence ranging between 5% and
7% for those aged ≥60 years and is a major cause of disability among older adults [4,5] AD is the
leading cause of dementia, responsible for two-thirds of all cases [6]. Since no causal treatment for AD
is available yet, prevention strategies, psychosocial interventions and symptomatic pharmacological
interventions are recommended and are central components of the treatment [7].
Up to now, research of causal therapies is focusing on the knowledge of typical neuropathological
features of AD like amyloid plaques and neurofibrillary tangles which are associated with the
tau-pathology [8,9]. In particular, the ß-amyloid hypothesis of AD has stimulated the development of
therapy concepts directed against the amyloid protein and amyloid deposits in the brain of patients
with AD.
One strategy is passive immunization with monoclonal antibodies which bind to ß-amyloid.
Although it has been demonstrated that these antibodies may reduce the amyloid burden in the brain
of AD patients, positive clinical effects were minimal or absent so far. Many promising compounds
like Bapineuzumab, Gantenerumab or Solanezumab have failed in phase III of clinical trials or are still
being evaluated (Aducanumab) [10–12].
Other ß-amyloid (Aß)-directed therapies focus on the enzymatic cleavage of the amyloid precursor
protein (APP). It is known that ß-secretases contribute essentially to the production of Aß40/42 which
is the toxic aggregating form of amyloid. Thus, ß-secretase inhibitors have been identified to be
therapeutically beneficial. However, recently, a world-wide clinical trial on the secretase inhibitor
Verubecestat was withdrawn because Verubecestat did not improve clinical ratings of dementia among
patients with prodromal Alzheimer’s disease. Some measures even suggested an impairment of
cognition and daily function compared to placebo [13].
The focus on Aß also led to the concept of removing it from plasma by therapeutic plasma exchange
(TPE). Aß is bound to serum albumin by >90% which in turn is removed and discarded by TPE [14,15].
TPE-treatment with albumin replacement favored the stabilization of cerebral perfusion in mild to
moderate AD patients compared to non-treated controls [15]. The same Spanish group currently
conducts a prospective multicenter, randomized, blinded and placebo-controlled, parallel-group,
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phase IIb/III trial in patients with mild to moderate AD (“Alzheimer’s Management by Albumin
Replacement (AMBAR)”). This study evaluates TPE with different replacement volumes of therapeutic
albumin (5% and 20%), with or without intravenous immunoglobulins and is still ongoing [14].
Another group sought to remove Aß and developed an ex vivo adsorptive filtration system that
resulted in an 80–100% reduction of Aβs within 30 min of circulation but has not yet been tested in
humans [16].
In view of the numerous negative results, it seems to be necessary to shift attention to new
therapeutic targets. In this respect, different pathologies of cognitive decline besides the Aß and the
tau-pathologies may be considered. Importantly, clinical, pathological and epidemiological data point
to a relevant overlap between cerebrovascular disease (CVD) and Alzheimer’s clinical syndrome [17].
Furthermore, cerebral microvascular lesions that are detected as white matter hyperintensities (WMH)
on magnetic resonance imaging (MRI) are associated with typical gray matter atrophy patterns of
AD in a considerable number of patients [18]. Thus, factors that alter the microenvironment of the
endothelium and the smooth muscle cells of blood vessels may compromise the molecular exchange
between blood and brain.
Rationale of the Clinical Investigation
Naturally occurring agonistic autoantibodies (agAABs) against G protein-coupled receptors
(GPCR) have been linked to cardiovascular disease such as dilated cardiomyopathy, myocarditis,
malignant hypertension, vascular renal rejection, diabetes mellitus type 2 or dementia [19]. Agonistic
AABs are functional antibodies that can activate the respective receptor. Agonistic AABs differ clearly
from non-functional AABs. The latter trigger autoimmune disease in an Fc-receptor mediated manner
whereas functional agAABs are able to bind cell receptors and activate intracellular signaling pathways
that are normally triggered by endogenous ligands [20]. A pathological example of agAABs is Graves’
hyperthyroidism with autoantibodies activating the thyroid-stimulating hormone (TSH)-receptor and
with subsequent overproduction of thyroid hormones [21]. Other examples for GPCR-agAABs are
AABs directed against adrenoceptors (AR; e.g., ß1AR and ß2AR, α1AR), the angiotensin (2) receptor
type 1 (AT-R1) and the endothelin receptor type A (ETA) [19]. The agAABs against AR are directed
against the first or second extracellular loop of the receptor. They bind to constant epitopes defined by
the amino acid sequence in the respective loop. These AABs belong to the immunoglobulin class G
(isotypes 1–3). GPCR-agAABs elicit a long-lasting dimerization of adrenoceptors and continuously
activate cellular processes such as phosphorylation of intracellular proteins and modulation of calcium
signaling that results e.g., in the case of agAABs against the α1AR in the proliferation of smooth
muscle cells and thickening of vessel walls [22]. In response to their natural agonists, the receptor
density on the cell membrane is regulated by receptor desensitization. This mechanism is inhibited
by agAABs [22]. In an animal model, continuous stimulation triggered by α1AR-AABs leads to
cerebrovascular remodeling and obliteration [23].
In a small clinical trial, treatment of Graves’ disease with rituximab, a B-cell depleting monoclonal
antibody specifically reduced the production of TSH-receptor antibodies [24]. In a case of thyreotoxic
crisis, TPE is also used to remove agAABs against TSH-receptor and albumin-bound thyroid
hormones [25].
Cerebrovascular remodeling may lead to disturbances in cerebral blood flow and a lack of outflow
of Aß. A clearing defect for Aß rather than an Aß-overproduction has been proven experimentally for
AD patients [26]. From this view, AABs against the α1AR may interfere with Aß clearance mechanisms
and act as a risk factor and a modulating component of dementia in patients with Alzheimer’s
clinical syndrome.
In line with this, the GPCR-α1AR was also reported to be a target for agAABs in patients with
essential and malignant hypertension [27]. In a pilot study in five α1AR-AAB-positive patients with
resistant hypertension, removal of these AABs by immunoadsorption lowered the mean arterial blood
pressure significantly by approximately 10 mmHg, and the effect was still present after 180 days [28].
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In line with this, a recent study in 816 subjects showed that the occurrence of α1AR-AABs predicted
arterial stiffness progression even in normotensives over a 5-year period [29].
A disease that has been very well investigated with regard to agAABs is dilated cardiomyopathy
(DCM). Among others, agAABs against the GPCR-ß1-adrenoceptor (ß1R) seem to play an important
role in DCM. Their elimination from the blood by immunoadsorption (IA) has been transferred to a
therapeutic intervention in clinical praxis. Removal of circulating antibodies by IA with subsequent
intravenous immunoglobulin G substitution (IA/IgG) has been shown to result in improvement of
cardiac function, in better exercise capacity, and in decrease of myocardial inflammation in DCM [30–33].
Removal of functional AABs does not have to be a constant process as in non-functional AAB triggered
disease. Already a one-week-course of IA seems to yield a so-called legacy effect that may persist for a
long time [34]. In DCM, removal of the agAABs by a one-week-course of IA lasts for up to 12 months
and even longer [35,36].
Noticeably, in dementia patients, agAABs against both the α1R- and ß2R-adrenoceptors were
also found at a prevalence of approx. 50%. Thus, in a primary care cohort who screened positive for
dementia, 40 out of 95 participants were also positive for agAAB (29 subjects with α1AR-AABs and 21
with ß2AR-AABs) [37]. However, agAABs could not discriminate between Alzheimer’s Dementia and
other forms of dementia. Patients with coronary heart disease were more likely (OR = 4.23) to have
α1AR-AABs than those without coronary heart disease. The presence of agAAB against adrenoceptors,
especially α1AR-agAABs, in persons suffering from dementia motivated a first pilot trial on the effects
of IA on the course of dementia [38]. In this trial, in four out of eight patients an effective depletion of
agAAB could be achieved by a 4-day per-protocol IA treatment, while another four patients received
a less effective 2–3 day treatment due venous access problems. IA was safe to use in these patients,
and the mean change in Mini Mental State Examination (MMSE) score of these patients remained
constant over 12 to 18 months.
The IMAD trial (Efficacy of immunoadsorption for treatment of persons with Alzheimer dementia
and agonistic autoantibodies against alpha1A-adrenoceptor) aims to ascertain whether the positive
effects of IA on slowing down dementia progression can be replicated. Moreover, IMAD will
comprehensively examine potential effects of this treatment in patients with Alzheimer’s clinical
syndrome by a combination of brain and vessel imaging along with cognitive tests and further
cardiovascular, cerebrovascular and laboratory examinations.
2. Methods
2.1. Objectives
The IMAD trial is designed as an exploratory monocentric interventional trial corresponding
to a proof-of-concept phase-IIa study. The aim of IMAD is to evaluate whether IA with subsequent
IgG-substitution (IA/IgG) is related to an improved uncorrected mean brain perfusion after 12 months
as a surrogate for potential beneficial effects on disease progression in patients with an Alzheimer’s
clinical syndrome and mild to moderate cognitive impairment. In addition, potential effects of IA/IgG
on cognitive measures as well as cardiovascular, cerebrovascular and laboratory parameters will
be investigated.
2.2. Patients
Potential participants for this trial need to have an Alzheimer’s clinical syndrome, according to
the definition as outlined in Jack et al. [39]. In patients without obvious exclusion criteria, cognitive
capacity is again assessed before inclusion using the MMSE. If a mild to moderate impairment (defined
by a MMSE score between 19 and 26) is confirmed, patients are tested for the presence of agAABs by an
ELISA-based method, followed by a bioassay-based confirmation test (methodological details are given
in Section 2.5.8). Patients with a positive test result by the bioassay are eligible for further screening.
We aim to include in total 15 patients with IA/IgG and 12 patients with complete follow-up data.
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2.3. Inclusion and Exclusion Criteria
Criteria that have to be fulfilled for all participants (inclusion criteria) and reasons that prevent
inclusion into the study (exclusion criteria) are summarized in Table 1.
Table 1. Inclusion and exclusion criteria.
Criteria
Inclusion
- Age 55–85
- Previous or suspected diagnosis of Alzheimer’s clinical syndrome
- Presence of agAAB against alpha1-adrenoceptor (α1AR)
- Mini mental state examination score between 19 and 26
- Written informed consent
Exclusion
- Presence of autoantibodies against the NMDA receptor
- Defective blood coagulation at time of inclusion
- Severe protein deficiency disorders
- Known manifest vitamin/folic acid deficiency (substitution allowed)
- Active infectious disease, or sings of ongoing infection with CRP >10 mmol/L
- Impaired renal function (serum creatinine >220 µmol/L)
- Any disease requiring immunosuppressive drugs or therapeutic antibodies
- Non-curative treated malignant disease or another life-threatening disease with poor
prognosis (estimated survival less than 2 years), except for basal-cell carcinoma
- Unstable angina pectoris, second or third degree atrioventricular block or
symptomatic sick sinus syndrome without implanted pacemaker, history of
myocardial infarction, bypass or other revascularization procedures, valvular heart
defect (≥2. degree)
- Severely reduced left ventricular systolic function (LVEF <30%) and/or heart failure
symptoms according to NYHA class III/IV
- Clinical manifestation of arterial disease, vascular surgery: ACl-Stenosis >60%; PAD
> IIb, history of stroke, diffusion disorder or expired territorial stroke in MRI
- Endocrine disorder excluding diabetes mellitus
- Severe hepatic disorder (Child–Pugh score 5 or more)
- Drug therapy against dementia since less than 3 months
- Psychopharmacological drug therapy since less than 3 months
- Dialysis requirement
- MRI contraindications (e.g., pacemaker)
- Legal tutelage
- Previous treatments with IA or immunoglobulins
- ACE-treatment during the IA
- Severe mental disorder (bipolar disorder, schizophrenia, depression)
requiring treatment
- Alcohol or drug abuse
- Inability to undergo the study procedure
- Participation in any other clinical/interventional study within less than 30 days prior
to screening
ACE, angiotensin converting enzyme; ACI, internal carotid artery; agAAB, agonistic autoantibodies; CRP, C reactive
protein; IA, immunoadsorption LVEF, left ventricular systolic function; MRI, magnetic resonance imaging; NMDA,
N-methyl-D-aspartate; NYHA, New York Heart Association; PAD, peripheral artery disease.
2.4. Study Design
During the screening phase, patients are checked for eligibility according the inclusion and
exclusion criteria (Table 1). Patients fulfilling these criteria are comprehensively examined during a
baseline visit, followed by IA/IgG treatment. All participants of the IMAD trial are followed up after 1,
6 and 12 months. The complete study flow is illustrated in Figure 1.
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The IMAD trial is an interdisciplinary project which involves the departments and institutes of
radiology, neurology, psychiatry, cardiology, nephrology and laboratory medicine of the University
Medicine Greifswald. The study complies with the Declaration of Helsinki and it has been approved by
the Ethics Committee of the University of Greifswald (MPG 02/16; MPG 02/16a). The trial is registered
at ClinicalTrials.gov (NCT03132272).
2.5. Examinations and Assessments
Patients undergo a comprehensive examination program including brain perfusion assessment by
MRI (primary outcome parameter: uncorrected mean brain perfusion assessed by arterial spin labeling
[ASL]) and assessment of further structural and vascular brain MRI parameters. In addition, several
cognitive, cardiovascular, cerebrovascular and laboratory parameters are assessed during baseline
and all follow-up visits. Table 2 gives an overview about methods, main parameters and respective
time points.
Table 2. Methods, main outcome parameters and time points.
Method Parameter Screening Baseline Follow-Ups Comments
Arterial Spin Labelling MRI Cerebral blood flow X X
MRI Basic protocol Brain Volume, WMH, CBM;MTA X X
Time-of-flight MR
angiography Vessel anatomy and size X X
Diffusion Tensor Imaging Fractional anisotropy X X
ADAS-Cog Cognition X X
MMSE Cognition X X X
GDS Depression X X
VLMT Cognition X X
Benton Test Cognition X X
Brachial blood Brachial blood pressure values X X X
Pulse wave analysis Arterial stiffness, centralhemodynamics X X
Digital endothelial vascular
function and stiffness
Endothelial function and
vascular stiffness X
Echocardiography Cardiac function and structure X
Transcutaneous oxygen
measurement Oxygenation X X
Kidney sonography Renal function X X
Doppler Sonography Carotid Arteria blood flow X X
Liquor analytics Tau/P-Tau (X) (X) Optional
Liquor analytics ß-A40/42 (X) (X) Optional
IA, immunoadsorption; MRI, magnetic resonance imaging; CBM, cerebral microbleeds; MTA, medial temporal lobe
atrophy; DTI, diffusion tensor imaging; ADAS, Alzheimer’s Disease Assessment Scale; MMSE, Mini-Mental State
Examination; GDS, Geriatric Depression Scale; VLMT, Verbal Learning and Memory Test; LVEF, left ventricular
ejection fraction; WMH, white matter hyperintensities; optional parameters are depending upon patient agreement;
follow-up visits are conducted 1, 6 and 12 months after IA treatment.
For examinations with a high potential for an observer bias (e.g., MRI, echocardiography), images
will be stored and the reading will be done offline in a blinded manner. Specifically, they will be
assessed without knowledge of the respective patient and time point. All examinations and methods
used are described in more detail in the following sections.
2.5.1. Brain Magnetic Resonance Imaging (MRI)
MR Imaging Protocol
All subjects undergo brain imaging at 1.5T (Magnetom Aera, Semens, Germany) using a 20-channel
head coil for image acquisition. Structural MR imaging protocol includes a sagittal 3D T1-weighted
sequence with an inplane resolution of 1 × 1 mm and a slice thickness of 1.3 mm (repetition time
[TR] = 1860 ms, echo time [TE] = 3.88 ms, inversion time [TI] = 1000 ms, 160 slices); a sagittal 3D
FLAIR dataset with 1 × 1 mm inplane spatial resolution and 1.1 mm slice thickness (TR = 5000 ms,
TE = 214 ms, TI = 1800 ms, field of view [FoV] = 265 × 265 mm); a diffusion weighted imaging (DWI)
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sequence with b-values 0/1000 s/mm2 (TR = 5600 ms, TE = 113 ms, 1.2 × 1.2 mm voxel size, 5 mm slice
thickness) and a time-of-flight angiography of the circle of Willis with 0.5 × 0.5 mm spatial resolution
with a slice thickness of 0.8 mm (TR = 31 ms, TE = 7.15 ms, FoV = 200 mm).
Cerebral perfusion is assessed using a 2D pseudo-continuous arterial spin-labeling sequence
(PICORE Q2T) with 5 mm slice thickness and an in-plane spatial resolution of 4 mm with 64 slices.
Other imaging parameters are a post labeling delay of 1.8 s, bolus duration of 700 ms, TR = 2500 ms
and TE = 13 ms.
A diffusion tensor imaging (DTI) dataset is acquired in all patients (TR = 4700 ms, TE = 116 ms,
b-value 0/1000 s/mm2, 12 directions) with a slice thickness of 4 mm and an in-plane spatial resolution
of 1.5 × 1.5 mm.
Total acquisition time is 42 min. All scans are checked by a board certified neuroradiologist for
gross abnormalities.
MR Image Analysis
For structural image analysis, all MR datasets are transferred to a dedicated Horos workstation
(www.horosproject.org). WMH are evaluated on axial reconstructions of the 3D FLAIR dataset with 3
mm slice thickness according to the Fazekas scale [40]. The Fazekas score are dichotomized into low
(Fazekas grade 0–1) and high (Fazekas grade 2–3). Cerebral microbleeds are defined as hypointense
lesions smaller than 10 mm on b = 0 diffusion weighted images. Lacunar lesions are defined as small
lesions in the deep white and grey matter with a diameter between 3 and 10 mm and cerebrospinal
fluid-like signal on all sequences. For quantitative analysis, lacunar lesions and microbleeds are
counted by visual inspection and for further statistical analysis dichotomized in present or absent.
Medial temporal lobe atrophy (MTA) score is rated on coronal reformations of the 3D T1w dataset
according to previously described criteria [41]. For statistical analysis, the mean MTA score of both
sides is dichotomized into high (>1.5) and low (≤1.5) as described elsewhere [42].
Vessel diameter of the internal carotid artery (ICA), the anterior (ACA) and middle cerebral artery
(MCA) and the basilar artery (BA) are evaluated by manual measurements. For the ICA, measurements
are performed at the level of the cavernous sinus, for the MCA in the median M1 segment, for the
ACA immediately distal the anterior communicating artery and for the basilar artery at the level of the
origin of the superior cerebellar artery, respectively.
Brain volume estimation are performed using T1w images. Therefore, the measured raw
DICOM data are converted into NIFTI (Neuroimaging Informatics Technology Initiative) format using
dcm2nii, which is part of the neuroimaging tool MRIcron. Preprocessing using FSL (version 6.0,
www.fsl.fmrib.ox.ac.uk/fsl) included correction for gradient nonlinearities, non-brain tissue removal,
linear registration to standard space, and tissue segmentation [43]. Evaluation of the pseudo-continuous
ASL images is performed as previously described by Binnewijzend et al. [43]. Therefore, ASL images
are also corrected for gradient nonlinearities in all three directions and then linearly registered to the
brain-extracted T1-weighted images. The brain mask is used to calculate uncorrected mean whole-brain
cerebral blood flow (CBF). These volume estimates are then transformed to the ASL data space to
correct partial volume-corrected cortical and white matter CBF maps [44]. CBF values are also extracted
using regions of interest (ROIs) in the frontal, temporal, occipital and parietal brain areas and the
hippocampus based on the MNI152 atlas and the Harvard–Oxford cortical atlas. The primary outcome
parameter of the study is uncorrected mean cerebral perfusion measured in mL/min/100 gr of brain
tissue determined by ASL.
Preprocessing of DTI data includes also conversion to NIFTI format. Then, the tool eddy
correct, part of FSL, is used to correct the diffusion-weighted data with respect to subject motion and
deformations introduced by eddy current artifacts of the MRI scanner. Fractional anisotropy (FA)
images are created by fitting a tensor model to the raw diffusion data using FSL DTI-FIT. FA analyses
was performed on a whole brain basis and using the ROI from CBF-analyses.
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2.5.2. Cognitive Assessment
Mini-Mental State Examination (MMSE)
We use MMSE-2 which is a revised version of the original MMSE [45,46] routinely used to measure
cognitive decline. The MMSE-2 consists of three versions: the standard version, the brief version and
the expanded version of the MMSE. In this study, the standard version is used in order to maximize the
benefit of the use of the scale while minimizing the duration of the cognitive assessment. The MMSE-2
shows a sufficient internal consistency (Cronbach’s alpha 0.66–0.79) [46].
Alzheimer’s Disease Assessment Scale - Cognition (ADAS-Cog)
The Alzheimer’s Disease Assessment Scale (ADAS) is commonly used to assess cognitive
dysfunction in individuals with Alzheimer’s Disease and other types of dementia [47,48].
The ADAS-Cog was developed as a two-part scale: one that measures cognitive impairment and one
that measures non-cognitive factors such as mood and behavior. In IMAD, only the cognitive scale of
the ADAS-Cog is applied, which consists of 11 parts and measures the cognitive functioning, language,
and memory in a 30-min test. Five parallel versions are available to avoid recall bias due to multiple
testing. The final score ranges from 0 to 70 points, with higher scores indicating more serious cognitive
impairment. The ADAS shows a good internal consistency (Cronbach’s alpha 0.61–0.76) [49]. During
the baseline visit, a cognitive profile over the 11 dimensions measured by the ADAS-Cog is created.
The profile is compared to reference values provided by Graham et al. [48] (Figure 2). According to the
reference values, the cognitive profile of patients with mild to moderate AD predominately shows
higher impairment in memory, and to a lesser extent, in cognitive functioning. In contrast, language is
hardly impaired in this stadium (Figure 2). Thus, patients with a different cognitive profile undergo
further examinations to exclude differential diagnoses. For patients included into the IMAD trial,
a cognitive change is estimated according to Stern et al. [50] to predict future cognitive decline during
the follow-up period. The estimated cognitive change is later compared to the observed cognitive
changes over 12 months after IA/IgG.J. Clin. Med. 20 0, 9, x FOR PEER REVIEW 10 of 24 
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Figure 2. Example of a patient’s cognitive profile of the Alzheimer’s Disease Assessment Scale–Cognition
(ADAS-Cog) with mild to moderate de entia from a patient included in the IMAD trial (own figure).
Continuous lin , cogni ve profile with mild to mod rate de entia; dash d line, cog itive profile with no
cognitive impairment; grey area, 95% confidence interv l for the gnitive profile. Without impa rment
according to Graham, Emery and Hodges [48].
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Verbal Learning and Memory Test (VLMT)
The Verbal Learning and Memory Test (VLMT) allows a short and individual assessment of
verbal learning and memory. The VLMT [51] uses 15 semantically independent words to assess verbal
memory. In a second step, an interference list with 15 new words is learned and recalled to distract
from the first, target list. After 20–30 min a delayed recall of the target list and a recognition test with a
new list combining the 30 learned words with 20 semantically and phonemically similar words is done.
Benton Test
The Benton Test (first edition: Benton, 1946) is a visual retention test for clinical use testing the
memory of visuo-spatial stimuli. The patient has to reproduce, draw or recognize presented graphic
stimuli. In this trial, instruction A (10 figures shown for 10 s) and parallel forms C, D and E are used.
The Benton Test has been shown to have a high internal consistency (Cronbach’s alpha = 0.94–0.98)
and validity [52].
Geriatric Depression Scale (GDS)
The Geriatric Depression Scale (GDS) is used to measure depressive symptoms in older persons.
It is a 15-item questionnaire demanding a dichotomous (yes/no) evaluation of depressive symptoms.
It was also shown to be applicable for persons with advanced cognitive impairment [53]. The GDS
shows a high internal consistency (Cronbach’s alpha 0.91).
The standardized questionnaires used in the IMAD trial as well as the respective cut-off values
applied are summarized in Table 3.
Table 3. Assessments by standardized questionnaires.
Test Abbreviation No Impairment Severe Impairment Normal Range
Mini-Mental State Examination MMSE 30 0 26–30
Alzheimer’s Disease Assessment
Scale—cognitive Scale ADAS-Cog 0 70 0–4
Memory 0 22 -
Cognitive Functioning 0 28 -
Language 0 15 -
Verbal Learning and Memory Test VLMT
Learning 75 0 48–75
Loss after Interference 0 15 -
Loss after Delay 0 15 0–3
Recognition 0 15 -
Benton Test Benton Test
Number Correct Score 10 0 -
Error Score 0 - -
Geriatric Depression Scale GDS 0 15 0–5
ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognition; VLMT, GDS, Geriatric Depression Scale; Verbal
Learning and Memory Test.
2.5.3. Cardiovascular Examinations
All cardiovascular examinations are conducted according to standardized procedures by certified
study nurses and physicians at the cardiovascular examination center of the German Centre
for Cardiovascular Disease (DZHK) in Greifswald. The following examinations are part of the
IMAD phenotyping:
Brachial Blood Pressure Measurement
Measurements of the brachial blood pressure are taken using an Omron 705 IT (OMRON Healthcare
Europe) blood pressure monitor with appropriate cuff size after a resting period of at least 5 min in
a sitting position. Accordingly, three measurements are taken on the right arm, with a 3-min break
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between each measurement [54]. All individual measurements (systolic blood pressure [mmHg],
diastolic blood pressure [mmHg], heart rate [/min]) are recorded.
Pulse-Wave Analysis and Central Hemodynamics
To perform cuff-based non-invasive data capturing at the brachial artery, the invasively validated
Mobil–O–Graph pulse-wave analysis (PWA) monitor (IEM GmbH, Stolberg, Germany) with inbuilt
ARCSolver algorithm is used [55,56]. After conventional blood pressure measurements, the brachial
cuff is inflated additionally to the diastolic blood pressure level and held for about 10 s to record
pulse waves. Subsequently, central pressure curves are automatically obtained through a transfer
function. In total, three measurements are taken, with a 3-min break between each measurement.
The following parameters are assessed by this method: pulse-wave velocity (PWV [m/s]), augmentation
index (Aix [%]), heart-rate corrected augmentation index (Alx@75 [%]), central systolic blood pressure
(cSBP [mmHg]), and central diastolic (cDBP [mmHg]).
Digital Endothelial Vascular Function and Stiffness
Digital pulse amplitude is measured with a pulse amplitude tonometry device placed on the tip
of the right index finger (Endo-PAT2000, Itamar Medical, Caesarea, Israel) [57]. This device comprises
a pneumatic plethysmograph that applies uniform pressure to the surface of the distal finger, allowing
measurement of pulse volume changes. Throughout the study, the inflation pressure of the digital
device is electronically set to 10 mm Hg below diastolic blood pressure or 70 mm Hg (whichever is
lower). Baseline pulse amplitude is measured for 2 min 20 s. Arterial flow is interrupted for 5 min
by a cuff placed on a proximal forearm using an occlusion pressure of 200 mm Hg or 60 mm Hg
above systolic blood pressure (whichever is higher). The pulse amplitude is recorded electronically
and analyzed by the computerized, automated algorithm of the device that provides the average
pulse amplitude for each 30-s interval after forearm cuff deflation up to 4 min [57]. The following
parameters which are known markers of endothelial function and vascular stiffness is derived from
these measurements: augmentation index (Aix [%]), heart-rate corrected augmentation index (AIx@75%
[%]), reactive hyperemia index (RHI) [57].
Transcutaneous Oxygen Pressure (tcPO2)
Transcutaneous oxygen pressure (tcPO2) measurements are performed with the PRÉCISE
8008 device (medicap GmbH, Ulrichstein, Germany). After a resting period of at least 10 min
in supine position, four probes are placed at the dorsum of the feet and at the back of both hands.
Measurements are taken while patients are breathing ambient air, in a resting supine position at
room temperature, between 22 ◦C and 25 ◦C. The site on the foot is carefully cleaned before the
probes are applied to the skin, using adhesive rings and contact liquid, supplied by the manufacturer.
The measurements are performed after calibration and preheating of the transducer to approximate
44 ◦C [58]. After termination of the procedure tcPO2 [mmHg] values for the four measurement sites
are recorded.
Echocardiography
Transthoracic echocardiography as a non-invasive gold standard for the determination cardiac
function and morphology is performed by certified physicians (Vingmed Vivid 9, 5S transducer
2.0–5.0 MHz, GE Medical Systems GmbH, Hamburg, Germany). All images and loops are stored
digitally and are analyzed offline. The reading of the echocardiograms is performed according to
current recommendations [59] includes parameters of left atrial and left ventricular (LV) structure
(left atrial diameter in parasternal short axis [mm]; left atrial volume in 4 chamber view [cm2],
enddiastolic/endsystolic thickness of the intraventricular septum and posterial wall [mm], LV mass [g],
enddiastolic/endsystolic LV volume [mL]) as well as LV systolic and diastolic function (biplane LV
ejection fraction according to Simpsons rule [%], global longitudinal strain [%], peak velocity of the
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mitral E- and A-wave [cm/s], deceleration time of the mitral E-wave [ms], isovolumetric relaxation
time [ms], peak velocity of the excursion of the lateral and septal mitral annulus in the early diastolic
phase [cm/s], ratio between the peak velocity of the excursion of the mean lateral/septal mitral annulus
in the early diastolic phase and the peak velocity of the mitral E-wave).
2.5.4. Kidney Function and Ultrasound
Kidney function is determined by blood and urinary laboratory tests: estimated glomerular
filtration rate by serum creatine and urinary albumin–creatinine ratio.
Renal ultrasound is performed with a HITACHI EUB-7500 machine. Kidney length is determined
as the maximum longitudinal dimension. Parenchymal thickness is measured as the shortest distance
from the renal sinus fat to the renal capsule at three different points: at the upper and lower pole
and at the middle. The parenchymal-pyelon-index is calculated as the sum of ventral and dorsal
parenchymal thickness (in a cross-section of the kidney) divided by the width of the central echo
complex. The following categories are generally assessed: location, anomalies as agenesis, hypo-
or hyperplasia, horseshoe kidney; kidney length; kidney width; parenchymal thickness; surface
roughness; echogenicity; parenchymal-pyelon-index; medullary or parenchymal calcification; number
and size of cysts, stones, infraction zones and tumors [60].
2.5.5. Ultrasound of the Extracranial Arteries
Ultrasound of the extracranial arteries is performed with a Philips UI 22 machine. Extracranial
carotid and vertebral arteries (VA) are examined with linear ultrasound transducers (bandwidth
3–13 MHz). Systolic, diastolic, and mean flow velocities in common carotid artery, internal carotid
artery (ICA), and V2 segments of VA are documented after angle correction. We classify ICA stenosis
uniformly according to current ultrasound criteria for grading internal carotid artery stenoses of
the the German Society of Ultrasound in Medicine (DEGUM) and Transfer to grading system of the
North American Symptomatic Carotid Endarterectomy Trial (NASCET) [61]: if peak systolic velocity
(PSV) is ≥125 cm/s, ICA stenosis is defined as being equivalent to ≥50% according to North American
Symptomatic Carotid Endarterectomy Trial criteria. Occlusion is defined by absence of Doppler and
color signal, typical proximal biphasic Doppler spectra, and additional indirect criteria like crossflow.
Carotid plaque is defined as any arterial wall irregularity thicker than 1.5 mm or exceeding >50% of
the surrounding wall thickness that protruded into the vessel lumen.
VA measurements are taken in the V2 segment and considered abnormal if there is direct
evidence of local or indirect evidence of proximal or distal flow abnormalities. Overall, abnormal flow
characteristic of the posterior circulation is defined by at least unilateral (1) flow abnormality of the
(extracranial) V2 segment of either VA, (2) intracranial VA stenosis or occlusion, or (3) basilar artery
(BA) stenosis or occlusion.
2.5.6. Blood and Urine Samples
Blood and urine samples are obtained according to standard operating procedures. In total,
403.7 mL blood and 42.0 mL urine are obtained per participant (250.0 mL for serum analysis, 121.5 mL
for plasma analytics, 16 mL EDTA, 16.2 mL Citrate). At the study center, samples are analyzed
immediately after blood and urine sampling. Two aliquots of 0.5 mL serum are stored in a freezer
(−80 ◦C) for further analysis.
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For sample analyses at independent laboratories (see Section 2.5.8), blood samples (170.0 mL
for serum analytics, 49.5 mL for plasma analytics) are collected at the study center. Further sample
management is accomplished by biometec GmbH, Greifswald, Germany.
Blood samples are obtained according to standard operating procedures. In total, 29 mL were
obtained per participant (8.5 mL for serum analysis, 8 mL for plasma analytics, 10 mL EDTA, 2.5 mL for
blood RNA). At the study center they were stored in a freezer at −80 ◦C). For this analysis, 100 aliquots
were available.
2.5.7. Laboratory Parameters
A complete list of the laboratory parameters can be found in the Appendix A (Table A1).
Laboratory analytics of blood and urine are carried out in accordance with established standard
operating procedures and preanalytical protocols follow the schemes of the GANI_MED (Greifswald
Approach to Individualized Medicine) project [62].
2.5.8. Assessment of Autoantibodies
An enzyme-linked immunosorbent assay (ELISA) is used to detect agAAB as described
previously [37,63]. Analyses are performed by an independent laboratory (E.R.D.E.-AAK-Diagnostik
GmbH, Berlin, Germany) blinded to clinical patient data. In brief, peptides are directed against the
ß1-adrenergic receptor loop 1 and ß2- adrenergic receptor loops 1 and 2. Modified peptides are bound
to 96-well streptavidin-coated plates. Peptides are coupled to preblocked streptavidin-coated 96-well
plates (Perbio Science, Bonn, Germany). Patient serum is added in a 1:100 dilution and incubated for
60 min. As detection antibody a horseradish peroxidase conjugated anti-human IgG antibody is used
(Biomol, Hamburg, Germany). Antibody binding is visualized by the 1-Step Ultra TMB ELISA (Perbio
Science, Bonn, Germany). The absorbance is measured at 450 nm against 650 nm with an SLT Spectra
multiplate reader (TECAN, Crailsheim, Germany).
As confirmation test, a bioassay is used that has been established by Wallukat and Wollenberger for
the identification and quantification of GPCR-AABs [64], and that has been modified and standardized
as described previously [65,66]. Analyses are performed by an external laboratory (Berlin Cures GmbH,
Berlin, Germany) without knowledge about any further patient characteristics or parameters. In this
bioassay, the chronotropic response of spontaneously beating cultured neonatal rat cardiomyocytes to
patients’ IgG-containing GPCR-AABs is recorded [67].
Anti-NMDA (N-methyl-D-aspartate) autoantibodies are determined in the participant’s sera by
immunohistochemistry according to manufacturer’s instruction (Anti-Glutamate-Receptor-IgG (Typ
NMDA)–IFFT, EUROIMMUN, Lübeck, Germany).
Additional measurements are performed by biometec GmbH, Greifswald. This includes
analyzes of antibodies against oxidized low-density lipoprotein (oxLDL) and β-amyloid, vasculitis
marker (aab against myeloperoxidase (anti-MPO), proteinase 3 (anti-PR3), glomerular basement
membrane (anti-GBM)), B-cell activity and antibody development (B-cell activating factor (BAFF)) and
neurodegeneration (neurogranin).
2.6. Intervention
Immunoadsorption is performed with ADAsorb apheresis devices equipped with Globaffin
adsorber columns in the dialysis department of the University Medicine Greifswald.
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The Globaffin column is a regenerative twin adsorber system that utilizes peptide ligands
(Peptid-GAM®; Fresenius Medical Care, Bad Homburg, Germany) covalently bound to sepharose.
These peptide ligands have a strong affinity for Fc fragments of immunoglobulins from any source
and selectively remove immunoglobulins and immune complexes from plasma without affecting
other plasma proteins. The Globaffin adsorber system has previously been used in antibody mediated
disorders, such as dilated cardiomyopathy and acute renal transplant rejection [68].
In contrast to unselective plasma exchange where all plasma components including albumin,
clotting factors and immunoglobulins are discarded and replaced with a fluid containing either albumin
and colloid or donor plasma, immunoadsorption is a semi-selective device. First, the patient’s plasma
is separated from blood cells by a membrane. Plasma is then passed over the Globaffin twin adsorber
system which selectively remove IgG, IgA, and IgM before the plasma is re-infused to the patient.
Typically, approximately four column volumes (250 mL) are processed before the plasma stream is
directed to the second column within the device and the first column undergoes a four-step regeneration,
so that the apheresis cycle can be reiterated: (1) replacement of residual plasma by 0.9% NaCl solution; (2)
elution of bound immunoglobulin by hydrochloric acid [glycine-HCl] buffer at pH 2.8; (3) neutralization
by phosphate buffered saline [PBS] and 4. replacement of PBS by 0.9% NaCl (Figure 3).
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A separate twin-column pair is assigned to each patient. A total of approximately 2.0-fold of
blood plasma volume is processed per day (approximately 4 to 6 h per session) on five consecutive
days. After the immunoadsorpti n eries, the patients receive 500 mg per kg body weight intrav ous
immunoglobulin s bstitution on day 6 (duri g pproximately 6 h). The dose is d termined based
on body weight and amounts to 500 mg/kg, depen ing on the packaging size. The eluates of the
regeneration of the columns are collected automatically and are used for detailed immunological
analyses. The patients are hospitalized for the immunoadsorption procedures and Ig substitution
period in the neurological department of the University Medicine Greifswald.
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2.7. Statistical Considerations
The objective of this trial is to assess the effects of IA/IgG in patients with agAABs and dementia in
patients with suspected Alzheimer’s clinical syndrome. The primary target parameter is uncorrected
mean cerebral brain perfusion as assessed by ASL 12 months after treatment.
2.7.1. Statistical Analyses
Analyses will follow an exploratory approach since we plan n = 15 subjects but do not consider a
comparison group. Although the main focus of analysis is descriptive, there is an interest in comparing
the development of outcomes of 1 month before and 12 months after IA/IgG.
Effect sizes will be estimated using appropriate (generalized) linear mixed regression models.
If necessary non-parametric models will be used. To evaluate effect sizes, suggestions according to
Cohen (1988) are used [69]. Analyses are performed as intention-to-treat (ITT) and per-protocol (PP).
2.7.2. Missing Data
Missing values are not replaced with substituted values. Due to the small sample size and the
exploratory character of the investigation, imputation techniques are not recommended.
2.7.3. Effect Size Consideration
Assuming a prevalence of agAABs of 31.5% and a drop-out rate of 20%, 120 participants have to
be checked for eligibility to reach the aim of 15 participants enrolled in the intervention. With a sample
size of n = 12, an expected α-error of 5% and a power of 80%, standardized effect sizes of 0.766 can be
detected (for one-sided paired t-tests), thus allowing a possible drop out of maximal 3 participants.
For data analyses, Stata (Version 14, StataCorp, College Station, TX, USA), SPSS statistics version
22 (IBM Corp., Armonk, NY, USA) or MATLAB (Version R2015a, Mathworks Inc., Natick, MA, USA)
will be used.
3. Discussion
The IMAD study investigates a new pathophysiological and therapeutic aspect of Alzheimer’s
clinical syndrome, the removal of α1AR-agAABs by immunoadsorption in patients with cognitive
impairment and suspected AD. Outcome parameters comprise cerebral blood flow measured
by arterial spin labelling MRI (primary), cognition measured by validated cognitive tests and
other questionnaires (ADAS-Cog, MMSE, VLMT, Benton Test, GDS) and vascular effects assessed
by echocardiography, sonography, blood pressure, pulse wave velocity, plethysmography and
transcutaneous oxygen measurement.
Extracorporeal therapies for dementia in Alzheimer’s clinical syndrome and CVD are innovative
therapeutic options. Recently, three different medical devices have been tested: dialysis, TPE and
IA. The Spanish AMBAR study is currently examining whether the peripheral lowering of Aß by
TPE and concurrent albumin substitution has an impact on cognitive performance [70]. Kitaguchi
and colleagues use dialysis systems [71] and adsorptive double-filtration systems [8] to lower the
plasma levels of Aß. Both groups are assuming that the removal of Aß may reduce the cerebral Aß
load. By using IA, we contrary aim to target vascular effects of α1AR-agAABs and only secondarily at
a probably better clearance of Aß. The IMAD study can profit from the experience of a previously
performed open pilot trial [38]. In this earlier study, the applicability of apheresis to dementia patients
and safety aspects were examined. The sustainability of the elimination of α1AR-agAABs was proven
and the first indications of a stabilization of cognitive performance were observed. The IMAD study
now investigates whether the removal of α1AR-AABs by a 5-day IA procedure has a positive effect
(improvement or non-deterioration) on impairment-relevant hemodynamic, cognitive, neurological,
vascular and metabolic parameters within a one-year follow-up period.
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As an exploratory trial, the IMAD study has, owing to feasibility constraints, a small projected
sample size in a monocentric, single-arm and unblinded design. Thus, only large effects can reach
statistical significance and, even then, the absence of a control group and other trial site(s) will still
confine the validity of the results. Nevertheless, this trial may provide important insights whether
eliminating or reducing α1AR-agAABs as a contributing factor of dementia-related cerebrovascular
impairment opens up a completely new treatment approach for α1AR-agAABs-positive persons along
the course of dementia progression in patients with Alzheimer’s clinical syndrome. It is of course
possible that other agAABs also play a role in the disease course, e.g., ß2AR which has been found in
dementia patients in previous studies [37,38].
In this respect, the comprehensive and extensive set of measured endpoints has the potential
to indicate possible intervention effects on a broad (patho)physiological spectrum. Indeed, the trial
protocol has been devised deliberately to comprise as many measurable physiological and metabolic
parameters as possible besides the neurocognitive tests. Therefore, the IMAD trial results will
allow to correlate intervention effects with potential physiological or functional mode(s) of action.
Such correlations may form the basis of targeted, larger and statistically more robust trials to specifically
and precisely uncover the effects of immunoadsorption on affected patients. In the future, the optimal
intervention time during the disease progression and the determinants that predict and govern the
response profile should be addressed in order to achieve a maximal beneficial effect of IA. In this
regard, one challenge will be to pinpoint the actual pathomechanistically active autoantibodies or
autoantibodies to delineate less-invasive specific depletion or inactivation schemes.
However, if the IA treatment approach does turn out to have a beneficial capacity for at least a
well-defined subgroup of patients at risk of dementia progression in Alzheimer’s clinical syndrome,
its one-time character (a single week of hospitalization) will certainly be advantageous, discarding or
at least attenuating the pharmacotherapeutic need for long-term compliance adherence. For reasons
that have not yet been clarified, the GPCR-AABs seldom reoccur after being removed—both in
DCM [36,72,73] and in dementia [38].
In the case of a positive outcome of the planned study, functional vascular improvement and
cognitive stability or improvement over at least 12 months, knowledge and experience should have
been gained to start a well-planned controlled, prospective, multicenter and randomized clinical study.
Its data could then be used to prove that IA is suitable for the treatment of mild and moderate dementia
with vascular pathological AABs and complements antidementive drug therapies with other targets.
Our study design has potential strengths and limitations that merit further discussion. We see the
interdisciplinary approach where knowledge from different disciplines and viewpoints are combined
as a unique strength. A further strength resulting directly from this is the comprehensive phenotyping
with different end-points to generate a broad spectrum of results that may help design a subsequent
multicenter pilot study. As a potential limitation we see the small sample size with low statistical
power. For this reason, we are also not able to investigate other potential risk factors (e.g., genetic
disposition). As we include patients with cognitive impairment without additional testing of CSF
biomarkers we face limitations in the diagnostic classification of their syndromes. Thus, we prefer
to label their impairments as suspected or probable AD. On the other hand, we use well-validated
neuropsychological testing (MMSE, ADAS-cog, Benton Test, VLMT) and carefully exclude many
medical conditions that could lead to secondary and potentially treatable dementia. Moreover, based on
the MRI scans we can exclude patients with organic/structural brain damages from the study. In fact,
our intention behind this patient selection was the inclusion of patients in their beginning or early phase
of probable AD to detect possible changes due to immunoadsorption in physiological and cognitive
parameters which might not occur in later states of dementia and to ensure the ability of collaboration
and adherence throughout a 12-months follow-up period of the study. Furthermore, we may miss
results in the long-term for future associations and detection of causalities due to the relatively short
follow up time of 12 months. Additionally, knowledge about the prevalence of agonistic autoantibodies
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in other forms of dementia and in the general population is limited. Keeping these limitations in mind,
our study is designed as an exploratory study and aims at showing proof of principle.
4. Conclusions
IMAD is an important pilot study that will analyze whether the removal of α1AR-agAABs by
immunoadsorption inα1AR-agAAB-positive persons slows the progression of dementia in Alzheimer’s
clinical syndrome and/or improves vascular functional parameters.
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Appendix A
Table A1. Laboratory parameters.
Parameter Screening Baseline
Immunoadsorption
Follow-Upsd1
Pre-IA
d1
Post-IA
d2
Pre-IA
d2
Post-IA
d3
Pre-IA
d3
Post-IA
d4
Pre-IA
d4
Post-IA
d5
Pre-IA
d5
Post-IA d6 Subst.
agAB A1AR X X
anti oxLDL X X X X X X X X X X X
anti MPO X X
anti PR3 X X
anti GBM X X
anti NMDA X
anti Amyloid ß X X X X X X X X X X X X
Neurogranin X X
Oxidized low density lipoprotein (oxLDL) X X
BAFF X X
Leucocytes X X X X X X X X
Erythrocytes X X X X X X X X
Hemoglobin X X X X X X X X
Hematocrit X X X X X X X X
Platelets X X X X X X X X
Mean Platelet Volume X X X X X X X X
Platelet Distribution Width X X X X X X X X
Lymphocytes X X X X X X X X
Prothrombin time (Quick) X X X X X X X X
International Normalized Ratio (INR) X X X X X X X X
Partial Thromboplastine Time (aPTT) X X X X X X X X
Mean Cell Volume (MCV) X X X X X X X X
Mean Cellular Hemogoblin (MCH) X X X X X X X X
Mean Cellular Hemoglobin Concentration
(MCHC) X X X X X X X X
Red Blood Cell Distribution Curve X X X X X X X X
Red Blood Cell Distribution Width (RBCD) X X X X X X X X
Sodium X X X X X X X X
Potassium X X X X X X X X
Calcium X X X X X X X X
Phosphate X X X X X X X X
Glucose X X X X X X X X
Creatinine X X X X X X X X
Urea X X X X X X X X
Uric Acid X X X X X X X X
Total Cholesterol X X X X X X X X
High density lipoprotein (HDL)-Cholesterol X X X X X X X X
Low density lipoprotein (LDL)-Cholesterol X X X X X X X X
Total Triglyzeride X X X X X X X X
Alanine Aminotransferase X X X X X X X X
Aspartate Aminotransferase X X X X X X X X
γ-Glutamyl Transferase X X X X X X X X
Total Bilirubin X X X X X X X X
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Table A1. Cont.
Parameter Screening Baseline
Immunoadsorption
Follow-Upsd1
Pre-IA
d1
Post-IA
d2
Pre-IA
d2
Post-IA
d3
Pre-IA
d3
Post-IA
d4
Pre-IA
d4
Post-IA
d5
Pre-IA
d5
Post-IA d6 Subst.
Lipase X X X X X X X X
C-reactive Protein (CRP) X X X X X X X X
Thyroid (TSH) X X X X X X X X
HbA1c X X X X X X X X
Albumin X X X X X X X X
Protein X X X X X X X X
Cystatin C X X X X X X X X
Fibrinogen X X X X X X X X
Complement C3 X X X X X X X X
Complement C4 X X X X X X X X
Factor VIII X X X X X X X X
Antithrombin X X X X X X X X
Immunoglobulin IgG1 X X X X X X X X
Immunoglobulin IgG2 X X X X X X X X
Immunoglobulin IgG3) X X X X X X X X
Immunoglobulin IgG4 X X X X X X X X
Immunoglobulin M X X X X X X X X
Immunoglobulin A X X X X X X X X
Total Immunoglobulin G X X X X X X X X X X X X X
Total Immunoglobulin X X X X X X X X
Vitamin B12 X X X X X X X X
25-Hydroxy-Vitamin D X X X X X X X X
Folic Acid X X X X X X X X
Homocysteine X
Specific gravity (Urine) X X X X X X X X
pH (Urine) X X X X X X X X
Leucocytes (Urine) X X X X X X X X
Nitrite (Urine) X X X X X X X X
Protein (Urine) X X X X X X X X
Glucose (Urine) X X X X X X X X
Ketone (Urine) X X X X X X X X
Urobilinogen (Urine) X X X X X X X X
Bilirubin (Urine) X X X X X X X X
Erythrocytes/Blood (Urine) X X X X X X X X
U-Creatine (Urine) X X X X X X X X
U-Protein (Urine) X X X X X X X X
U-Albumin (Urine) X X X X X X X X
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